# SLV-324 Treatment of Metastatic Solid Tumors

> **NCT07108114** · PHASE1 · RECRUITING · sponsor: **Solve Therapeutics** · enrollment: 70 (estimated)

## Conditions studied

- Metastatic Solid Tumors

## Interventions

- **DRUG:** SLV-324 intravenous (IV infusion)

## Key facts

- **NCT ID:** NCT07108114
- **Lead sponsor:** Solve Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2027-05
- **Final completion:** 2027-08
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07108114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07108114, "SLV-324 Treatment of Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07108114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*